Enzymatica AB: The board of directors in Enzymatica has resolved on a directed share issue of SEK 40.3 million
30 August 2016 - 5:16PM
Press release
Lund on August 30, 2016
The board of directors in Enzymatica has resolved
on a directed share issue of SEK 40.3 million
The board of directors in
Enzymatica AB (publ) (the "Company") has on August 30, 2016
resolved to, pursuant to the authorization granted by the Annual
General Meeting held on 25 May 2016, issue 17,500,000 new shares
with deviation from the shareholders' pre-emptive rights. The share
issue is directed to Abanico Invest AB (Mats Andersson), Fibonacci
Asset Management AB (Björn Algkvist) and RoosGruppen AB (Håkan
Roos), a limited group of new and existing long-term
investors.
The subscription price of SEK 2.30 per share
corresponds to a discount of approximately 4.2 per cent compared to
one month volume weighted average price on Nasdaq First North
Stockholm, and the board of directors considers the subscription
price to be in accordance with the market based on the current
industry and market conditions, as well as in relation to the
volume and objective of the share issue. The Company has been
engaged in discussions with the share subscribers and the reasons
to deviate from the existing shareholders' pre-emptive rights are
due to the possibility to raise new working capital in a time and
cost efficient way in order to strengthen the Company's cash
position and to create a financial stability. The new share issue
increases the number of shares in the Company with 17,500,000
shares from 73,387,808 shares to 90,887,808 shares in total, which
corresponds to a dilution of approximately 19 per cent, and
increases the share capital by SEK 700,000.23 from SEK 2,935,513.27
to SEK 3,635,513.50 in total.
Statement from Fredrik Lindberg,
CEO Enzymatica AB (publ):
We are very pleased to have attracted these long-term and
experienced investors. With this capital injection we are pursuing
our financing plan and it creates a financial stability for the
business and our international expansion, says Fredrik
Lindberg.
For
more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
This information is information
that Enzymatica AB (publ) is obliged to make public pursuant to the
EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out
above, at 0920 CET on August 30, 2016.
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on six markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit
www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser
Bankaktiebolag.
Enzymatica_ Press release directed
share issue 160830
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024